32 related articles for article (PubMed ID: 20413453)
1. A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis.
Padmapriyadarsini C; Szumowski JD; Akbar N; Shanmugasundaram P; Jain A; Bathragiri M; Pattnaik M; Turuk J; Karunaianantham R; Balakrishnan S; Pati S; Agibothu Kupparam HK; Rathore MK; Raja J; Naidu KR; Horn J; Whitworth L; Sewell R; Ramakrishnan L; Swaminathan S; Edelstein PH
medRxiv; 2023 Aug; ():. PubMed ID: 37577511
[TBL] [Abstract][Full Text] [Related]
2. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.
Fromm MF; Dilger K; Busse D; Kroemer HK; Eichelbaum M; Klotz U
Br J Clin Pharmacol; 1998 Mar; 45(3):247-55. PubMed ID: 9517368
[TBL] [Abstract][Full Text] [Related]
3. Specific N-demethylation of verapamil by cytochrome P450 from
Shen C; Liu H; Dai W; Liu X; Liu J; Yu B
Eng Life Sci; 2019 Apr; 19(4):292-301. PubMed ID: 32625009
[TBL] [Abstract][Full Text] [Related]
4. Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects.
Rebello S; Compain S; Feng A; Hariry S; Dieterich HA; Jarugula V
J Clin Pharmacol; 2011 Nov; 51(11):1549-60. PubMed ID: 21406600
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Risk Management and Hepatitis C: Combining Drugs.
Smolders EJ; Ter Horst PJG; Wolters S; Burger DM
Clin Pharmacokinet; 2019 May; 58(5):565-592. PubMed ID: 30259390
[TBL] [Abstract][Full Text] [Related]
6. A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.
Tod M; Goutelle S; Bleyzac N; Bourguignon L
Clin Pharmacokinet; 2019 Apr; 58(4):503-523. PubMed ID: 30194612
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects.
Dingemanse J; Nicolas L
Clin Drug Investig; 2013 Mar; 33(3):207-13. PubMed ID: 23381958
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren: clinical experience and future perspectives of renin inhibition.
Sureshkumar KK; Vasudevan S; Marcus RJ; Hussain SM; McGill RL
Expert Opin Pharmacother; 2008 Apr; 9(5):825-37. PubMed ID: 18345958
[TBL] [Abstract][Full Text] [Related]
10. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
11. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
13. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
15. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
